NEW YORK, Nov. 8, 2013 /PRNewswire/ -- In response to the disturbing fact that people are more likely to die of a heart attack in New York City than anywhere else in the U.S., medical device company Itamar Medical (TASE: ITMR), today announced the launch of its first-ever initiative in the U.S. to increase awareness of endothelial (arterial) function testing and the importance of early detection in preventing heart attacks, particularly for symptomatic patients. The New York area was selected as the first city to kick off "Don't Ignore Your EndoScore" The campaign rolls out in New York the week of November 11.
The campaign will focus on providing information and options to help individuals, families and communities to best maximize their heart health, and will include testing with Itamar's EndoPAT test at participating New York-based hospitals and medical practices. To further promote heart health among families, the company also is offering a voucher program that provides for a second free test for a family member or loved one whenever someone takes an EndoPAT test during the month of November
"Testing for endothelial health plays an early and important role in stratifying cardiovascular risk," said Steven Lamm, MD, Clinical Assistant Professor, Department of Medicine (GIM Division), New York University School of Medicine, Director, Men's Health, NYU Medical Center. "The clinical value of this testing has been confirmed in many peer-reviewed studies, and it has been incorporated into regular use by many leading cardiologists around the world."
The EndoPAT test, an innovative, non-invasive FDA-approved medical device for measuring endothelial (arterial) function, is similar to having your blood pressure tested (both use a standard blood pressure cuff) and is easily performed in a p
|SOURCE Itamar Medical|
Copyright©2012 PR Newswire.
All rights reserved